Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
IGBP1 antisense RNA 1 (IGBP1-AS1) is a long non-coding RNA (lncRNA) transcribed from the antisense strand of the IGBP1 locus on chromosome X (Xq13.1). It is classified as a non-coding RNA with very low protein-coding potential. Functionally, IGBP1-AS1 has been shown to inhibit proliferation and invasion of breast cancer cells in vitro and in vivo, enhance apoptosis, and act as a tumor suppressor in these contexts. Mechanistically, it regulates a feedback loop involving miR-24-1 and the transcription factor ZIC3, serving as an RNA sponge for miR-24-1, which in turn upregulates ZIC3, with ZIC3 further activating IGBP1-AS1 expression. Downregulation of IGBP1-AS1 is associated with reduced overall and progression-free survival in breast cancer patients, indicating its potential as a prognostic biomarker, although its disease and mechanistic roles outside cancer remain largely undefined. There are currently no known direct drug interactions, and it is not considered a direct therapeutic target such as a receptor, enzyme, or transporter.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on IGBP1 antisense RNA 1 (IGBP1-AS1).